SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 5,000 ordinary shares on October 12, 2026, at a weighted average price of $7.2606 per share. The sales were made pursuant to a duly adopted trading plan under Rule 10b5-1(c); individual transaction prices ranged from $7.17 to $7.38. He directly held 195,993 shares after the sale.
SOPHiA GENETICS SA (SOPH) Chief Scientific Officer Zhenyu Xu sold 4,000 ordinary shares on October 13, 2026, at a weighted average price of $7.1818 per share. The shares were sold in multiple transactions at prices ranging from $7.09 to $7.24 under a Rule 10b5-1(c) trading plan. After the sale, Xu directly held 541,493 ordinary shares.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong sold 8,500 Ordinary Shares on October 12, 2026, at a weighted average price of $7.2554 per share. The shares were sold in multiple transactions at prices ranging from $7.15 to $7.38 per share, pursuant to a duly adopted Rule 10b5-1(c) trading plan. Camblong reported direct holdings of 3,387,150 shares following the sale.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 6,168 ordinary shares on October 5, 2026, at a weighted average price of $8.1226 per share. The sales satisfied tax withholding obligations arising from restricted stock units vesting on October 2 and 3, 2026, and were made under a pre-established Rule 10b5-1(c) trading plan; the filing says they were not discretionary trades. Van Well directly held 332,716 shares after the sale.
SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 4,240 ordinary shares on October 5, 2026, at a weighted average price of $8.1338 per share. The open-market sales satisfied tax withholding obligations arising from restricted stock unit vesting on October 2 and 3, 2026. They were made under a pre-established Rule 10b5-1(c) trading plan and were not discretionary. Manuela Valente directly held 206,210 ordinary shares after the sale.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma sold 5,284 ordinary shares on October 5, 2026, at a weighted average price of $8.1243 per share. The sales satisfied tax withholding obligations arising from restricted stock unit vesting on October 2 and 3, 2026, and were made under a pre-established Rule 10b5-1(c) trading plan; the footnote says they were not discretionary trades. Verma directly held 166,887 shares after the sale.
SOPHiA GENETICS SA (SOPH) Chief Sales Officer Kevin Puylaert reported two direct sales of ordinary shares on October 5, 2026: 185 shares at $8.06 per share and 31 shares at $7.92 per share. No Rule 10b5-1 plan is reported.
George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, sold 1,592 ordinary shares on October 5, 2026, at a weighted-average price of $8.1014 per share. The sale satisfied tax withholding obligations arising from restricted stock units that vested on October 2, 2026. It was made under a pre-established Rule 10b5-1(c) trading plan adopted by Cardoza and was described as non-discretionary. His direct holdings following the sale were 306,726 ordinary shares.
SOPHiA GENETICS SA (SOPH) Chief Medical Officer Philippe Menu sold 7,394 ordinary shares on October 5, 2026, at a weighted average price of $8.1282 per share. The shares were sold in multiple transactions at prices from $7.91 to $8.30 to satisfy tax withholding obligations tied to restricted stock units that vested October 2 and 3, 2026. The sale was made under a pre-established Rule 10b5-1(c) trading plan adopted by Menu and did not represent discretionary trades; he directly held 200,993 shares afterward.
SOPHiA GENETICS SA (SOPH) Executive Chairman Jurgi Camblong sold 40,172 ordinary shares on October 5, 2026, at a weighted average price of $8.1282 per share; multiple transactions were priced from $7.90 to $8.35 per share, inclusive.
The sales were made in the open market to satisfy tax withholding obligations arising from restricted stock units that vested on October 2 and 3, 2026. They were effected under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Camblong directly held 3,395,650 ordinary shares after the sale.